---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-023428"
form_type: "8-K"
ticker: "BTCY"
cik: "0001630113"
company_name: "BIOTRICITY INC."
filed_at: "2023-07-05T23:59:59+00:00"
generated_at: "2026-06-13T12:42:08.108704+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biotricity FY23 revenue up 26% to $9.64M, net loss narrows; 1:6 reverse split effective July 3

## Summary
- FY23 revenue grew 26% YoY to $9.64M; net loss decreased 35% to $19.5M.
- Recurring Technology Fees rose 49% to $8.8M, 71% gross margin; blended margin 57%.
- Q4 revenue $2.74M (+28% YoY); net loss $4.9M vs $6.0M a year ago.
- 1-for-6 reverse split to maintain Nasdaq $1 minimum bid; shares reduce to ~8.5M.
- Company targets positive cash flow by end of CY2024.

## SEC filing metadata
- accession: 0001493152-23-023428
- form_type: 8-K
- ticker: BTCY
- cik: 0001630113
- company_name: BIOTRICITY INC.
- filed_at: 2023-07-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630113/000149315223023428/0001493152-23-023428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630113/000149315223023428/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-023428
- JSON: https://secwatch.observer/filing/0001493152-23-023428.json
- Plain text: https://secwatch.observer/filing/0001493152-23-023428.txt

## Key facts
- Earnings Releases
  BIOTRICITY INC. reported fiscal 2023 year and (unaudited) fourth quarter ended March 31, 2023 results: revenue $9.64 million, net income $19.5 million, EPS $0.38 per share.
  - Period: fiscal 2023 year and (unaudited) fourth quarter ended March 31, 2023
  - Revenue: $9.64 million
  - Net income: $19.5 million
  - EPS: $0.38 per share
  - Result: reported results
  source text: Cash Flow ● Company advancing toward positive cashflow likely by end of CY 2024 ● Accelerating product sales, and customer re-order revenue, ● FY23 revenue rose 26% YOY to $9.64 million on 5% lower SG&A of $17.6 million ● Improving gross margins currently at 57% despite reduced, loss-leader device pricing to boost recurring ‘Technology Fees,’ lower customers’
  evidence_url: https://www.sec.gov/Archives/edgar/data/1630113/000149315223023428/0001493152-23-023428-index.htm
- Governance Changes
  BIOTRICITY INC.: Effected a 1-for-6 reverse stock split via Certificate of Amendment to Amended and Restated Articles of Incorporation (effective 2023-07-03).
  - Change: charter amendment
  - Effective: 2023-07-03
  source text: On June 29, 2023, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation to effect a one-for-six (1-for-6) reverse split (the “Reverse Split”). The Reverse Split became effective on July 3, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1630113/000149315223023428/0001493152-23-023428-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.